BTAI
BioXcel Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.52 EPS, $262K rev
Last earnings -5.8% on 2026-05-15
$1.31
▲ +4.80%$1.31▼ -20.61%
over 1Y
L $1.02EODHDH $6.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.8%
1W+0.8%
1M+0.0%
3M+4.0%
YTD-22.9%
1Y-20.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity -1.47x); but revenue fell -71.7% YoY.
Revenue (FY2025) $642K · FY2025
BioXcel Therapeutics, Inc. shows $642K in FY2025 revenue (-71.7% YoY), a -10887.4% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $375K | $1.38M | $2.27M | $642K |
| Gross profit | — | — | — | — | — |
| Operating income | -$107M | -$160M | -$172M | -$67.2M | -$50.5M |
| Net income | -$107M | -$166M | -$179M | -$59.6M | -$69.9M |
| Diluted EPS | -$4.05 | -$5.92 | -$98.33 | -$23.51 | -$5.73 |
| Net margin | — | -44201.9% | -12974.9% | -2630.1% | -10887.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$117M
EV / EBITDA—
EV / Sales181.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-197.1%
FCF yield-162.4%
Quality & risk
ROIC (est.)—
Free cash flow-$57.6M
Total debt$110M
Net cash-$81.2M
Altman Z-Score-26.23 distress
Piotroski F-Score2/8
Capital returns
Buyback yield25.4%
Dividend yield (est.)—
Shareholder yield25.4%
Shares Δ YoY+393.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-05-042026-05-22open ↗4Period ending 2026-05-042026-05-22open ↗4Period ending 2026-05-042026-05-22open ↗4Period ending 2026-05-042026-05-22open ↗144Filing2026-05-20open ↗144Filing2026-05-20open ↗144Filing2026-05-20open ↗144Filing2026-05-20open ↗
Frequently asked
- Is BioXcel Therapeutics, Inc. (BTAI) a buy?
- BTAI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.47x); but revenue fell -71.7% YoY.
- What is BioXcel Therapeutics, Inc.'s quality score?
- BTAI scores 18.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001720893, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 6:59:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.